CA2271941A1 - Imidazoles a substitution triaryle et leurs procedes d'utilisation - Google Patents

Imidazoles a substitution triaryle et leurs procedes d'utilisation Download PDF

Info

Publication number
CA2271941A1
CA2271941A1 CA002271941A CA2271941A CA2271941A1 CA 2271941 A1 CA2271941 A1 CA 2271941A1 CA 002271941 A CA002271941 A CA 002271941A CA 2271941 A CA2271941 A CA 2271941A CA 2271941 A1 CA2271941 A1 CA 2271941A1
Authority
CA
Canada
Prior art keywords
pyridyl
imidazole
fluorophenyl
chlorophenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002271941A
Other languages
English (en)
Inventor
Linda L. Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9700559.9A external-priority patent/GB9700559D0/en
Application filed by Individual filed Critical Individual
Publication of CA2271941A1 publication Critical patent/CA2271941A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des 2,4-Diaryl-5-pyridylimidazoles qui constituent des antagonistes de glucagon. Ces composés bloquent l'action du glucagon sur son récepteur. Ainsi, ces composés peuvent s'utiliser dans la prophylaxie ou le traitement d'affections chez les mammifères se manifestant par des taux élevés de glucagon. Le diabète, l'obésité, l'hypertension, la cachexie et d'autres affections similaires constituent des exemples de telles affections.
CA002271941A 1996-11-20 1997-11-17 Imidazoles a substitution triaryle et leurs procedes d'utilisation Abandoned CA2271941A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3146896P 1996-11-20 1996-11-20
US60/031,468 1996-11-20
GB9700559.9 1997-01-13
GBGB9700559.9A GB9700559D0 (en) 1997-01-13 1997-01-13 Triaryl substituted imidazoles and methods of use
PCT/US1997/020955 WO1998022108A1 (fr) 1996-11-20 1997-11-17 Imidazoles a substitution triaryle et leurs procedes d'utilisation

Publications (1)

Publication Number Publication Date
CA2271941A1 true CA2271941A1 (fr) 1998-05-28

Family

ID=26310784

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002271941A Abandoned CA2271941A1 (fr) 1996-11-20 1997-11-17 Imidazoles a substitution triaryle et leurs procedes d'utilisation

Country Status (5)

Country Link
EP (1) EP0959885A4 (fr)
JP (1) JP2001504489A (fr)
AU (1) AU726311B2 (fr)
CA (1) CA2271941A1 (fr)
WO (1) WO1998022108A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
CA2673615C (fr) 2000-01-21 2013-07-16 Novartis Ag Combinaisons comprenant des inhibiteurs de la dipeptidylpeptidase- iv et des agents antidiabetiques
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
WO2002040445A1 (fr) 2000-11-17 2002-05-23 Novo Nordisk A/S Agonistes de glucagon/antagonistes inverses
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2003024447A1 (fr) * 2001-09-20 2003-03-27 Smithkline Beecham Corporation Inhibiteurs de glycogene synthase kinase-3
MXPA04002931A (es) * 2001-10-12 2005-04-11 Bayer Pharmaceuticals Corp Heterociclos que contienen nitrogeno de 5 miembros sustituidos con fenilo para el tratamiento de la obesidad.
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
WO2004058727A1 (fr) * 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation 3,5-dihydro-4-h-imidazol-4-ones substitues utilises dans le traitement de l'obesite
AU2004210127B2 (en) 2003-01-27 2009-10-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
CA2547785A1 (fr) 2003-12-19 2005-07-21 Merck & Co., Inc. Guanidines cycliques, compositions contenant de tels composes et procedes d'utilisation
ES2306165T3 (es) 2004-06-04 2008-11-01 MERCK & CO., INC. Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso.
AU2005272043B2 (en) 2004-07-07 2010-07-29 Merck Sharp & Dohme Corp. Pyrazole amide derivatives, compositions containing such compounds and methods of use
US7625938B2 (en) 2004-07-22 2009-12-01 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
AU2006227435A1 (en) 2005-03-21 2006-09-28 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives
JP2008534593A (ja) 2005-03-30 2008-08-28 メルク エンド カムパニー インコーポレーテッド グルカゴン受容体アンタゴニスト化合物、そのような化合物を含む組成物、及びその使用方法
JP2009502923A (ja) 2005-07-26 2009-01-29 メルク エンド カムパニー インコーポレーテッド 置換ピラゾールを合成するための方法
BRPI0616077B8 (pt) 2005-09-14 2021-05-25 Takeda Pharmaceuticals Co composição farmacêutica formulada em uma dose única, kit, artigo de manufatura, uso da composição farmacêutica e uso de um ou mais compostos antidiabéticos
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
AU2007229850A1 (en) 2006-03-23 2007-10-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AU2007254329A1 (en) 2006-05-16 2007-11-29 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
DK2531501T3 (en) 2010-02-03 2014-02-24 Takeda Pharmaceutical APOPTOSESIGNALREGULERENDE KINASE 1 inhibitors
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
ES2926931T3 (es) * 2014-02-07 2022-10-31 Agency Science Tech & Res Inhibidores de caseína quinasa 1 basados en azoles 2,4,5-tri-sustituidos como inductores de la cardiomiogénesis
WO2016141381A2 (fr) * 2015-03-05 2016-09-09 University Of Notre Dame Du Lac Potentialisateurs d'antibiotiques bêta-lactames
US11958828B1 (en) 2023-11-07 2024-04-16 King Faisal University 4,5-bis(4-bromophenyl)-1-hexyl-2-(3-pyridyl)-1H-imidazole as an antimicrobial compound
US11993575B1 (en) 2023-12-29 2024-05-28 King Faisal University Ethyl [4,4-bis(4-bromophenyl)-2,5-dioxoimidazolidin-1-yl]acetate as an antimicrobial compound
US11970462B1 (en) 2024-01-03 2024-04-30 King Faisal University Ethyl 3-[4,4-bis(4-chlorophenyl)-2,5-dioxoimidazolidin-1-yl]propanoate as an antimicrobial compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US4430326A (en) * 1981-12-22 1984-02-07 University Patents, Inc. Method of diminishing glucose levels resulting from endogenous glucagon
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation

Also Published As

Publication number Publication date
EP0959885A4 (fr) 2002-07-17
AU5441498A (en) 1998-06-10
AU726311B2 (en) 2000-11-02
JP2001504489A (ja) 2001-04-03
EP0959885A1 (fr) 1999-12-01
WO1998022108A1 (fr) 1998-05-28

Similar Documents

Publication Publication Date Title
AU726311B2 (en) Triaryl substituted imidazoles and methods of use
AU730295B2 (en) Triaryl substituted imidazoles as glucagon antagonists
US5880139A (en) Triaryl substituted imidazoles as glucagon antagonists
AU728760B2 (en) Triaryl substituted imidazoles, compositions containing such compounds and methods of use
JP6967112B2 (ja) 新規なフェロポーチン阻害剤
US5837719A (en) 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5776954A (en) Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
EP1458383B1 (fr) Modulateurs pyrazole a substitution heteroaryle du recepteur 5 metabotropique de glutamate
JP4648703B2 (ja) 医薬としての新規なアミノインダゾール誘導体及びこれらを含む医薬組成物
DE69736642T2 (de) Heterocyclische Verbindungen, ihre Herstellung und Verwendung
US7105548B2 (en) Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
JP5276445B2 (ja) ｍＰＧＥＳ−１阻害剤としての２−（フェニルまたは複素環）−１Ｈ−フェナントロ［９，１０−ｄ］イミダゾール類
JPH10503211A (ja) 炎症の処置のための１，２−置換イミダゾリル化合物
CA2468067A1 (fr) Modulateurs du recepteur metabotropique 5 du glutamate
US5955480A (en) Triaryl substituted imidazoles, compositions containing such compounds and methods of use
KR20130083470A (ko) 알도스테론 신타제 및 아로마타제의 억제를 위한 축합된 이미다졸로 유도체
EA021025B1 (ru) Соединения, эффективные в качестве ингибиторов ксантиноксидазы, способ их получения и содержащая их фармацевтическая композиция
CA2513631A1 (fr) Derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2002532495A (ja) ヘテロアリール環状アセタール類
KR20050109074A (ko) 이미다졸-4-일-에티닐-피리딘 유도체
JPH11506123A (ja) キノキサリンジオン類
KR20230159839A (ko) 글리코겐 합성효소 1(gys1)의 저해제 및 이의 사용 방법
FR2844267A1 (fr) Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
CA2373882A1 (fr) Composes dotes d'une activite inhibitrice de la cytokine
CN114746408A (zh) 炔基-(杂芳基)-甲酰胺hcn1抑制剂

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead